AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy
MWN-AI** Summary
At the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026, Santhera Pharmaceuticals presented data demonstrating the long-term effectiveness and safety of AGAMREE® (vamorolone) in treating Duchenne muscular dystrophy (DMD). The findings show that vamorolone maintains similar effectiveness in delaying loss of ambulation compared to traditional corticosteroids like prednisone and deflazacort, with no significant statistical differences in time to loss of ambulation (p=0.8587, p=0.6544, respectively).
Significantly, patients treated with vamorolone experienced an 80% lower incidence of vertebral fractures (8.1% vs. 41.9% with deflazacort, p=0.0082), and showed a 12.17 cm average height advantage over those on classic corticosteroids, which are known to stunt growth (p<0.0001). Additionally, the incidence of cataracts was dramatically lower with vamorolone (5.3% vs. 37.8% for deflazacort, p=0.015), with no cases of glaucoma reported. Overall, the safety profile of vamorolone appears favorable, suggesting reduced risks linked to traditional corticosteroid treatment.
The median exposure duration for patients on vamorolone was approximately five years, and over this period, maintenance of normal growth trajectories without compromising efficacy was achieved. While both treatment groups experienced an increase in BMI z-scores, the growth and bone health of vamorolone-treated patients remained within normal limits.
These results underscore vamorolone as a promising alternative to corticosteroids, aimed at improving long-term outcomes for DMD patients without the severe side effects associated with current treatment standards. The ongoing GUARDIAN study will continue to assess the long-term benefits and risks of vamorolone, contributing to the evolving treatment landscape for DMD.
MWN-AI** Analysis
Santhera Pharmaceuticals' AGAMREE® (vamorolone) has made significant strides in the treatment of Duchenne muscular dystrophy (DMD), as evidenced by the promising data unveiled at the MDA 2026 conference. With comparable long-term effectiveness to traditional corticosteroids, namely prednisone and deflazacort, AGAMREE® offers a robust alternative that mitigates common side effects associated with these conventional treatments.
Analysts should note the substantial statistically meaningful differences in safety profiles, particularly concerning vertebral fractures and cataracts. The data indicates an impressive 80% reduction in vertebral fractures in patients treated with vamorolone compared to deflazacort (8.1% versus 41.9%, p=0.0082). Additionally, a lower incidence of cataracts (5.3% for vamorolone vs. 37.8% for deflazacort, p=0.015) highlights its appeal in maintaining patient quality of life over extended periods.
AGAMREE® also showcased the potential for sustained growth trajectories, with a striking 12.17 cm mean height advantage over patients using traditional corticosteroids, a crucial consideration for pediatric patients. This underscores the growing consensus that vamorolone provides effective treatment without compromising growth—a critical factor for families dealing with DMD.
Investors and market analysts should consider these findings when assessing Santhera's market position. As the treatment landscape evolves towards combination therapies and as ongoing studies like GUARDIAN collect further real-world data, AGAMREE® appears poised to capture a larger market share. The drug's unique mechanism of action, designed to dissociate efficacy from common steroid-related toxicities, positions it favorably for adoption in clinical settings.
Overall, the compelling efficacy and safety data, combined with the increasing importance of tolerance in long-term treatment, suggest that investors could see Santhera Pharmaceuticals as a promising prospect in the therapeutic space for rare neuromuscular diseases. Close monitoring of ongoing data and market reaction will be essential for maintaining an informed investment approach.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Comparable long-term effectiveness to classic corticosteroids, both prednisone (p=0.8587) and deflazacort (p=0.6544), based on time to loss of ambulation
- 80% fewer patients with vertebral fractures (8.1% vs 41.9% on deflazacort, p=0.0082)
- Maintenance of normal height with 12.17 cm mean height advantage vs classic corticosteroids where significant stunting was observed (p<0.0001)
- Cataracts in 5.3% vs 37.8% patients, significantly lower than deflazacort (p=0.015); no glaucoma observed
Pratteln, Switzerland, March 9, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced that full results from long-term real-world comparative analyses, including baseline data from the ongoing GUARDIAN study of AGAMREE® (vamorolone), were presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026 in Orlando, Florida.
The dataset includes up to eight years of AGAMREE exposure (median approximately five years) in boys with Duchenne muscular dystrophy (DMD). The analyses incorporate data from participants in clinical studies who continued treatment through various access programs as well as the Phase 4 GUARDIAN study (NCT06713135). Long-term data including baseline results from GUARDIAN were compared to a propensity-matched historical control cohort treated with deflazacort or prednisone.
Together, the data demonstrate that vamorolone maintains long-term effectiveness comparable to traditional corticosteroids, while improving tolerability and meaningfully reducing key steroid-associated side effects that often lead to dose reductions or discontinuations that impact long-term patient outcomes.
These data were presented during the MDA poster session on Sunday, March 8, 2026 (6:00–8:00 pm ET). In addition, Catalyst Pharmaceuticals, in conjunction with Santhera, will host an MDA Industry Forum titled “Vamorolone in DMD: Real-World Experience, Emerging Questions and the Path to Long-Term Evidence” on Tuesday, March 10, 2026, from 12:00–1:30 pm ET in the Key Largo Room, The Hilton Orlando, Orlando, FL. The forum will be presented by Craig McDonald, MD, Professor of Physical Medicine & Rehabilitation and Pediatrics, UC Davis Health.
Comparable Long-Term Effectiveness
There was no statistically significant difference in time to loss of ambulation (LoA) between pooled vamorolone doses (2–6 mg/kg/day) and classic corticosteroids (p=0.9041), or vs deflazacort (p=0.6544) and prednisone (p=0.8587) individually. The mean real-world vamorolone dose was 4.5 ± 1.8 mg/kg/day, with median exposure of approximately 5 years. These findings suggest that improved long-term safety outcomes can be achieved without compromising efficacy and that real-world dosing indicates patients may tolerate higher doses of vamorolone over the long term compared with experience using classic corticosteroids.
Maintained Growth Without Compromising Motor Function
Height trajectories were maintained on vamorolone, while growth decline and stunting were observed in classic corticosteroid cohorts as expected. Growth stunting was defined as a height z-score < –2.0, which is approximately two standard deviations below age-matched healthy boys, a commonly used threshold for clinically meaningful short stature. After 5 years, the mean height difference was +12.17 cm in favor of vamorolone. Importantly, vamorolone is the first dissociative corticosteroid to demonstrate patients with DMD can achieve normal growth without compromising efficacy. BMI z-scores increased in both treatment groups, consistent with corticosteroid class effects.
Substantially Lower Vertebral Fracture Risk
After a median treatment duration of approximately five years, there was an 80% reduction in the proportion of patients with vertebral fractures (8.1% of vamorolone-treated boys vs 41.9% in boys treated with deflazacort, p=0.0082).
Non-vertebral fractures occurred in 27.5% of patients, including long bone fractures in 12.5%, which are at the lower end of rates reported in the literature for traditional corticosteroids, indicating a favourable profile for chronic use. Bone age remained within normal limits relative to chronological age on vamorolone, whereas delays are commonly reported with classic corticosteroids.
Favorable Long-Term Ocular and Metabolic Profile
Cataracts were observed in significantly fewer patients compared with deflazacort (5.3% vs 37.8%, p=0.015) and numerically lower vs prednisone (5.3% vs 12.1%, p=0.05). No cases of glaucoma were observed. Glucose and lipid parameters were within normal ranges in the majority of patients. Morning cortisol levels were consistent with expected adrenal suppression for corticosteroid therapy, and no new safety signals were identified.
Ongoing Data Collection
The prospective GUARDIAN study will continue to assess long-term outcomes over the coming years, including anthropometrics, muscle function, bone health, cardiac and respiratory function, eye health, pubertal development, and additional safety endpoints.
Shabir Hasham, Chief Medical Officer of Santhera, said: “These longer-term analyses contribute to a growing body of evidence characterising the clinical profile of vamorolone as patients remain on therapy over extended periods of time. The data presented at MDA continue to indicate that vamorolone maintains effectiveness comparable to traditional corticosteroids, while showing improvements in steroid-associated safety and tolerability outcomes. As the treatment landscape for Duchenne muscular dystrophy continues to evolve, with increasing use of combination treatment strategies, understanding the long-term benefit–risk profile of corticosteroid therapy is particularly important. A treatment that preserves efficacy while reducing treatment-limiting adverse effects would be better suited to support long-term disease management, including in combination with emerging therapies. The ongoing GUARDIAN study will continue to expand our understanding of vamorolone across a broader range of real-world outcomes as patients age and remain on treatment.”
About AGAMREE® (vamorolone)
AGAMREE is a novel drug with a mode of action based on binding to the same receptor as glucocorticoids but modifying its downstream activity. Moreover, it is not a substrate for the 11-?-hydroxysteroid dehydrogenase (11?-HSD) enzymes that may be responsible for local drug amplification and corticosteroid-associated toxicity in local tissues [2-5]. This mechanism has shown the potential to ‘dissociate’ efficacy from steroid safety concerns and therefore AGAMREE is positioned as a dissociative anti-inflammatory drug and an alternative to classic corticosteroids, the current standard of care in children and adolescent patients with DMD [2-5].
In the pivotal VISION-DMD study, AGAMREE met the primary endpoint Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment and showed a good safety and tolerability profile [2, 5]. The most commonly reported side effects were cushingoid features, vomiting, weight increase and irritability. Side effects were generally of mild to moderate severity.
Currently available data show that AGAMREE, unlike classic corticosteroids, has no restriction of growth [6] and no negative effects on bone metabolism as demonstrated by normal bone formation and bone resorption serum markers [7].
? This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
References:
[1] Dang UJ et al. (2024) Neurology 2024;102:e208112. doi.org/10.1212/WNL.0000000000208112. Link.
[2] Guglieri M et al (2022). JAMA Neurol. 2022;79(10):1005-1014. doi:10.1001/jamaneurol.2022.2480. Link.
[3] Liu X et al (2020). Proc Natl Acad Sci USA 117:24285-24293
[4] Heier CR et al (2019). Life Science Alliance DOI: 10.26508
[5] Ward et al., WMS 2022, FP.27 - Poster 71. Link.
[6] Hasham et al., MDA 2022 Poster presentation. Link.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Commission (EC), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in Switzerland by Swissmedic, in China by the National Medical Products Administration (NMPA), in Hong Kong by the Department of Health (DoH) and in Canada by Health Canada. Santhera has out-licensed the rights to AGAMREE as follows: to Catalyst Pharmaceuticals for North America; to Sperogenix Therapeutics for China and certain countries in Southeast Asia; and to Nxera Pharma for Japan, South Korea, Australia, and New Zealand. For further information, please visit www.santhera.com.
AGAMREE® is a trademark of Santhera Pharmaceuticals.
For further information, please contact:
Santhera
Catherine Isted, Chief Financial Officer:
IR@santhera.com
ICR Healthcare:
Santhera@icrhealthcare.com
Stifel
Brough Ransom, Charles Hoare, Fred Walsh
+44 (0)20 7710 7600
Octavian
Serge Monnerat, Marius Zuberbuehler
+41 (0)44 520 1588
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
Attachment
FAQ**
How does the long-term effectiveness of AGAMREE® (vamorolone) compared to classic corticosteroids like prednisone and deflazacort, particularly regarding the statisitically insignificant differences in time to loss of ambulation as noted in the Santhera Pharms Hldgs Ltd SPHDF findings?
Given the significant reduction in vertebral fracture rates for vamorolone (8.1% vs 41.9% for deflazacort), how might this influence treatment preferences among healthcare providers when prescribing for Duchenne muscular dystrophy, as presented by Santhera Pharms Hldgs Ltd SPHDF?
With a mean height advantage of 12.17 cm observed for vamorolone-treated patients versus classic corticosteroids, how should investors assess the long-term market potential of AGAMREE® in light of the benefits highlighted in the Santhera Pharms Hldgs Ltd SPHDF analysis?
Considering the significantly lower occurrence of cataracts in vamorolone-treated patients (5.3% vs 37.8% for deflazacort), what implications does this have for the overall safety profile of medicines from Santhera Pharms Hldgs Ltd SPHDF in treating Duchenne muscular dystrophy?
**MWN-AI FAQ is based on asking OpenAI questions about Santhera Pharms Hldgs Ltd (OTC: SPHDF).
NASDAQ: SPHDF
SPHDF Trading
0.0% G/L:
$19.95 Last:
800 Volume:
$19.95 Open:
